Hepatic gene therapy might correct the clinical manifestations of several genetic disorders in patients. Although retroviral vectors with a strong liver-specific promoter can result in stable and therapeutic levels of expression of genes from the liver, application of these techniques in humans is limited by the need to perform one or more invasive procedures to achieve ex vivo or in vivo transduction of hepatocytes. In vivo delivery involves injection of retrovirus into the portal vein during liver regeneration. Although transduction is efficient and specific for the liver, induction of hepatocyte replication requires a 70% partial hepatectomy or administration of a liver toxin. An altemative method for inducing hepatocyte replication is to occlude branches of the portal vein. This results in apoptosis of hepatocytes in the occluded lobes and compensatory replication of the hepatocytes in the nonoccluded lobes. We demonstrate here that portal branch occlusion is nearly as effective as partial hepatectomy at facilitating retroviral vector transduction in vivo and has a lower morbidity. Portal branch occlusion could be performed in larger animals by minimally invasive techniques and has been used safely to treat human patients with liver cancer. Portal branch occlusion might ultimately be used in humans to facilitate retroviral vector transduction in vivo for the treatment of genetic diseases.
OVERVIEW SUMMARY
Retroviral vectors can result in long-term expression of genes from the livers of animals. However, the methods that have been used to transduce Uver cells in vivo carry a significant risk to human patients. The goal of this study was to identify a safe method for facilitating retroviral vector transduction of Uver ceUs in animals. Portal branch occlusion (PBO) was performed to induce Uver ceU repUcation, and a retroviral vector was injected into the portal vein at various times thereafter. Transduction was assessed by the level of expression of the serum protein human ai-antitrypsin in blood for 2 months after transduction. PBO was almost as effective as partial hepatectomy at faciUtating retroviral vector transduction and had less morbidity. PBO might be used to faciUtate in vivo retroviral transduction in humans for the purpose of gene therapy.
INTRODUCTION ENE THERAPY INVOLVES TRANSFER OF A GENE that CUCOdcS a functional protein into the appropriate ceUs of a patient
with an acquired or congenital genetic disorder. Hepatic gene therapy might be used to tteat serum protein deficiencies such as hemophiUa or metaboUc defects such as famiUal hypercholesterolemia or phenylketonuria. Adenoviral vectors and plasmid DNA can be deUvered to the liver by inttavenous injection. Expression is ttansient in most animals, however, due to rejection of the adenovirus-ttansduced cells and the instabiUty of plasmid vectors (Ledley, 1993; Thompson, 1995; Ponder, 1996) . In conttast, rettovttal vectors result in long-term expression because of their abiUty to integrate into the chromosome.
Although rettoviral vector-mediated hepatic gene therapy is an atttactive approach for the permanent correction of genetic disorders, two problems have Umited its use in humans: (i) low or unstable expression; and (ii) risks of the delivery method (Ledley, 1993; Thompson, 1995; Ponder, 1996) . Most experiments using rettoviral vectors have observed low-level expression because of a low ttansduction efficiency and/or low-level expression per copy Kay et al, 1992 Kay et al, , 1993 Rettinger et al, 1994) . Recently, we made progress in overcoming the expression problem by identifying a promoter that resuUs in high-level and stable expression 'Departments of Intemal Medicine and Biochemistty and Molecular Biophysics, ^Department of Surgery, and 'Departments of Radiology and CeU Biology and Physiology, Washington Umversity School of Medicine, St. Louis, MO 63110.
of human ai-antitiypsin (hAAT) from a rettovttal vector in the Uver (Okuyama et al, 1996) . Using this vector, we achieved therapeutic levels of functional coagulation Factor X in rat blood for over 10 months (Le et al, in press) . Despite this success, the manipulations required to achieve ttansduction of hepatocytes with a rettovttal vector currently Umit its appUcation for the tteatment of human genetic diseases.
Both ex vivo and in vivo methods for modification of hepatocytes with a rettovttal vector have significant risks (Ponder, 1996) . The ex vivo approach involves hepatocyte isolation, in vitro ttansduction, and infusion of tiie genetically modified ceUs into tiie portal vein. Hepatocyte isolation requttes a surgical procedure to obtain 5-10% of the liver, because hepatocyte repUcation in vitro is Umited. In addition, the collagenase perfusion method for isolating single-ceU suspensions of hepatocytes and the large-scale in vitro culture leads to the possibility of contamination. Finally, infusion of hepatocytes into the portal vein could lead to portal vein thrombosis. Although infusion of ~ 1-5% of the normal hepatocyte number into mice (Ponder et al, 1991) , rabbits (Wdson et al, 1990; , dogs (Kay et al, 1992) , baboons (Grossman et al, 1992) , or humans (Grossman et al, 1995) was well tolerated, infusion of more hepatocytes led to portal vein thrombosis and death in a high percentage of mice (K.P.P. and S.L.C. Woo, unpubUshed data).
Metiiods for in vivo deUvery of a rettovttal vector to the Uver also have significant risks for patients. Induction of Uver regeneration is necessary because Moloney murine leukemia virus (Mo-MLV)-based rettovttal vectors only integrate into dividing cells (Miller et al, 1990) , and hepatocytes are normally quiescent. In most studies, Uver regeneration has been induced by performing a 70% partial hepatectomy (Ferry et al, 1991; Rettinger et al, 1994 ). An altemative approach is to induce hepatocyte repUcation by the administtation of a Uver toxin. Indeed, administtation of carbon tettachloride (Kaleko et al, 1991) or an adenovttal vector that encodes a protein that is toxic for the Uver (Lieber et al, 1995a,b) has been used by others to faciUtate rettovttal vector ttansduction. Although these methods were effective, Uver toxins might occasionally result in death due to Uver insufficiency, making thett use less acceptable for human patients.
The goal of this study was to identify a safe method for inducing the hepatocyte replication that is necessary for in vivo ttansduction with a MoMLV-based rettovttal vector. The portal vein provides -65% of the blood to the Uver, with the hepatic artery supplying the rest (Taylor et al, 1979) . Portal branch occlusion (PBO) rapidly induces apoptosis of hepatocytes in the Uver whose blood supply is compromised and compensatory replication of the remaining hepatocytes. The Ugated lobes atrophy to 10% of their original weight within 2 weeks after PBO, whereas the nonoccluded lobes enlarge to restore the original Uver mass (Rozga et al, 1986) . PBO was associated with surprisingly littie morbidity in rats and has been used safely in human patients to treat primary or metastatic Uver cancer (Honjo et al, 1975; Kinoshita et al, 1986; Makuuchi et al, 1991; DeBaere et al, 1993) . We demonsttate here that PBO is nearly as effective as partial hepatectomy at faciUtating rettoviral vector transduction in vivo, but has less morbidity. PBO might be used to faciUtate retroviral vector transduction in humans for the purpose of gene therapy if its efficacy and safety can be demonstrated in large animals.
MATERIALS AND METHODS

Chemicals and reagents
All chemicals and reagents were purchased from Sigma Chemical (St. Louis, MO) unless otherwise stated. hAAT-540B is an LNL-6-derived (MiUer and Rosman, 1989 ) rettovttal vector that contains the 600-bp apoUpoprotein E enhancer, the 402-bp hAAT promoter, die 1.3-kb hAAT cDNA, and the 1.2-kb intemal ribosome entiy site (IRES)-mutant dihydrofolate reductase (*DHFR) cassette. It was designated ApoE(-)hAAT-LTR in a previous report (Okuyama et al, 1996) . The titer of this vector had decUned from its initial value of 10 X 10^ cfii/ml to 1 X 10' cfu/rcd at the time of this smdy. Goat anti-bromodeoxyuridine (BrdU) antibody was a generous gift of Dr. Steve Cohn.
Surgical procedures
Sprague-Dawley rats weighing 200-250 grams (Harlan Sprague-Dawley, IndianapoUs, IN) were maintained under standard institutional care. Rats received anesthesia with inhaled methoxyfluorane. Partial hepatectomy involved removal of the left and medial lobes and was performed as previously described (Rettinger et al, 1994) . Portal vein Ugation was performed using sUght modifications to a previously reported procedure (Rozga et al, 1986) . The abdomen was entered through an upper midUne incision that extended above the xiphoid. The left and medial lobes of the Uver were displaced cephalad against the diaphragm, and the intestines were eviscerated and reflected to the left. The duodenum was reflected to the left to expose the hepatoduodenal Ugament, and the porta hepatis was visuaUzed with a 50 X operating microscope (Week OM-1505). The hepatic artery and common bile duct were bluntly dissected free from the bifurcation of the portal vein and reflected to the left. The superior branch of the portal vein was Ugated with 7-0 siUi (DeKnayel, FaU River, MA) . This generally resulted in pallor of the left and medial lobes and engorgement of the right and caudate lobes. If no blanching occurred, vessels to the individual lobes were Ugated. The abdomen was closed in a single layer witii mnning 4-0 nylon (Etiiilon; Etiiicon, Somerville, NI). The sham operation involved opening the abdomen and dissecting the portal vein free from the hepatic artery and common bde duct.
Liver biopsy and portal vein injection of rettovttal vector were performed 18-72 hr after portal branch occlusion. The abdomen was entered tiu-ough tiie previous incision by removing the sutures witii a forceps and nerve hook, taking care to avoid any mtestines adhering to die anterior abdominal wall. Some animals received biopsies of a lobe whose blood supply was not occluded. The distal 0.5 cm of die inferior portion of die right lobe, representing <5% of die liver mass, was Ugated widi 4-0 Polyglactin 910 (Vicryl; Educon) and the distal portion amputated, leaving a small stiimp distal to die tie. Hemostasis was achieved widi microfibrillar collagen (Avitene; Medchem Products, Wobum, MA) and compression. If die right lobe was inaccessible due to adhesions, die caudate lobe was exposed by entering the lesser sac and biopsied as above. All animals received a portal vein injection of rettoviral vector. This was performed immediately after wedge Uver biopsy for those animals that received one. The duodenum was reflected to the left to expose the portal vein on die dorsal surface of the pancreas. The portal vein was entered 5-10 mm from its bifurcation with a 30-gauge needle, keeping the bevel up and in view at all times to avoid punctitting tiie back wall of tiie vein. Four milliliters of conditioned medium containing the rettoviral vector and 8 /ig/ml Polybrene were injected into the portal vein, which resulted in blanching of the perfused lobes. At die completion of the injection, the needle hole was compressed with a cottontipped swab soaked in thrombin (Thrombostat; Parke-Davis, Morris Plains, NJ), and a smaU piece of Surgicel (Johnson and Johnson, New Bmnswick, NJ) appUed with gentle compression until hemostasis was achieved. The abdomen was closed in two layers using mnning Vicryl for the muscle and fascia and mnning 4-0 nylon for the skin.
hAAT EUSA Semm was collected and assayed by ELISA as reported previously (Rettinger et al, 1994) . All samples were diluted appropriately to give a concenttation that fell on the Unear portion of the standard curve.
BrdU labeling 5-Bromo-2'-deoxyuridine (BrdU) labeling was performed in some rats. Approximately 3 ml of a solution containing 6.6 mg/ml of BrdU and 0.66 mg/ml of 5-fluoro-2'-deoxyuridine (FldU) in phosphate-buffered saUne (PBS, 139 mM NaCl, 2.7 mM KCl, 8.1 mM NaP04, 1.5 mAf KPO4) was injected into tiie peritoneum at a dose of 100 mg/kg and 10 mg/kg for BrdU and FldU, respectively. A small wedge biopsy of the Uver was obtained 4 hr later and frozen immediately in OCT compound (Miles, Inc., Elkhart, IN) . Eight /im-thick frozen sections were mounted on sUdes and fixed for 20 min in 10% formaldehyde in water. Unless otherwise stated, incubations were performed at room temperature and slides were washed in H2O between different solutions. SUdes were tteated with 0.05 mg/nd trypsin in TBS (100 mM NaCl, 50 mM Tris[hydroxymethyl]aniinomethane-HCl pH 7.5) for 10 min, washed, incubated with 0.3% hydrogen peroxide in TBS for 10 min, washed, and tteated with 2 N HCl and 0.3% Triton X-100 for 30 min. Sections were washed with H2O and incubated with affinity-purified goat antiBrdU antibody (Cohn and Lieberman, 1984) at a 1:500 dilution in TBS with 5% dry miUc (Schnuck's Grocery, St. Louis, MO) and 0.3% Triton X-100 (TBS-milk) ovemight at 4°C. SUdes were washed in TBS and incubated with horseradish peroxidase (HRP)-coupled anti-goat sheep IgG at a 1:200 dilution in TBS-milk for 60 min at room temperatare, washed in TBS, and developed with 3,3'-diaminobenzidine (DAB) tettahydrochloride (Harlow and Lane, 1988) . Twenty random fields containing >2,000 cells were analyzed for the number of brown nuclei. SUdes were then stained with hematoxylin to identify aU nuclei, and the number of cells in each field was counted. The ratio was used to determine the labeUng index.
Aruilysis of liver function tests
Diagnostic kits from Sigma Chemical were used to quantitate the Sigma-Frankel units/ml of semm glutamic pymvic ttansaminase (SGPT) and the mg/dl of total bilimbin in rat semm. The SGPT and biUmbin assays was performed as suggested by the suppUer except that 4 pl or 20 pl, respectively, of semm was assayed, the volumes of other reagents were scaled down proportionately according to the manufactarer's recommendations, and the sample O.D. was quantitated in an ELISA reader at the appropriate wavelength.
RESULTS
PBO can facilitate retroviral vector transduction of rat liver
The goal of this study was to determine if PBO could facUitate rettovttal vector transduction of the Uver in vivo. At various times after PBO, a rettovttal vector was injected into the portal vein and the transduction efficiency was assessed. The rettovttal vector hAAT-540B was chosen because it directed expression of hAAT cDNA for 18 months from the Uver in vivo (Okuyama et al, 1996 ; T. Okuyama and K.P.P., unpublished data). Previous stadies showed an absence of semm hAAT when an hAAT-expressing rettovttal vector was injected into the portal vein of a normal animal, demonsttating the requttement for repUcating hepatocytes for ttansduction to occur (Rettinger et al, 1994) . Furthermore, the semm hAAT was directiy proportional to the number of rettoviral particles deUvered, demonsttating that semm hAAT could be used to assess the ttansduction efficiency.
The rat Uver contains four lobes. The left and medial lobes comprise ~ 70% of the Uver, whereas the right and caudate lobes make up the remainder. In this stady, the portal vein branch that served the left and medial lobes of the Uver was ligated in an attempt to induce regeneration of the remaining Uver. Positive conttol rats received surgical removal of the left and medial lobes (70% partial hepatectomy). Negative conttol rats received a sham operation in which the Uver was not damaged. Rettovttal vector was injected into the portal vein of rats at various times after these tteatments, and ttansduction was assessed by determining the semm level of the reporter gene hAAT at weekly intervals. Expression in individual rats was stable for 2 months after deUvery (data not shown), which is consistent with our previous results demonsttating that this vector results in long-term expression from the Uver in vivo. The individual data points obtained over this 2-month interval were averaged to give the hAAT level for an individual rat.
iiAAT levels for individual rats of each group were averaged and the standard error of the mean (SEM) calculated. Figure  IA shows the average semm hAAT for animals that received a single dose of rettovttal vector at 24 to 48 hr after PBO. Conttol rats that received rettovttal vector injection at 24 h after partial hepatectomy expressed hAAT at 63.2 ± 22 ng/ml. This is lower than what was observed in previous experiments (Okuyama et al, 1996) because fewer rettovttal particles were injected in this stady due to a decUne in the titer and die use of unconcenttated rettovttal vector. Rats that underwent the sham Efficacy of ttansduction when rettovttal vector is injected at 24-^8 hr after PBO (Experiment 1). Rats received one of the following tteatments: occlusion ofthe portal vein branches that supply blood to 70% of die Uver, 70% partial hepatectomy (PH), or a sham laparotomy in which the liver was not damaged (Sham). At various times after this procedure, 4 ml containing ~ 4 X 10^ cfu of hAAT-540B rettovttal vector was injected into the portal vein. For each animal, the semm hAAT was deterrmined at weekly intervals and was stable for 2 months after fransduction (data not shown). The average hAAT level for each rat over these 2 months was determined. The hAAT level of rats of various groups was determined by averaging the semm hAAT levels for individual rats. This average ± SEM for that group is reported. The number of animals (N) in each group is listed undemeath the bar. An asterisk above the bar indicates conditions in which the semm hAAT level was statistically different from the level observed in rats that received the rettoviral vector at 24 hours after partial hepatectomy (p < 0.05). B. Efficacy of rettovttal ttansduction when rettovttal vector is injected at 18-72 hr after PBO (Experiment 2). Rats were tteated as described in A, except only 1 X 10^ cfu of hAAT-540B rettovttal vector in 4 ml was injected into the portal vein. The average seram hAAT ± SEM was determined. The asterisk indicates conditions in which the semm hAAT level was statistically different from the level observed in rats that received the rettovttal vector at 24 hr after partial hepatectomy (p < 0.05).
operation had no detectable semm hAAT, demonsttating the requttement for replicating hepatocytes for ttansduction to occur. Rats that underwent PBO and were injected with the rettovttal vector 24-48 hr later had seram hAAT levels that were approximately 20-50% as high as the level observed in rats that underwent partial hepatectomy and received the rettovttal vector 24 hr later. Although the hAAT level in the rats that received rettoviral vector at 48 hr after PBO was significantly lower that the level in rats that received rettovttal vector at 24 hr after partial hepatectomy, the hAAT level was not significantly different in rats that received retroviral vector at 48 hr after PBO as compared with rats tiiat received rettovttal vector at 24-44 hr after PBO. Therefore, we conclude diat rettovttal vector ttansduction is faciUtated to a similar extent at 24-48 hr after PBO.
A repeat experiment was performed to define better the time interval after PBO during which rettovttal ttansduction could occur. As shown in Fig. IB , die seram hAAT observed after injection of rettovttal vector at 18 hr or 72 hr after performing PBO was only 5% or 14%, respectively, of tiie hAAT level observed after injection of rettovttal vector at 40 hr after PBO. This demonsttates that rettovttal vector ttansduction was considerably lower at these timepoints. Injection of rettovttal vector into rats at 40 hr after performing PBO again resulted in seram hAAT levels that were approximately 50% of diat observed after injection at 24 hr after partial hepatectomy. We conclude that the ttansduction efficiency is ~ 25-50% as high when the rettovttal vector is injected at 24-^8 hr after performing portal branch occlusion as when the vector is injected at 24 hr after partial hepatectomy. Transduction is less efficient when the rettovttal vector is injected before 18 hr or after 72 hr foUowing PBO.
Quantitation ofthe labeling index
Because ttansduction with a Mo-MLV-derived rettovttal vector requttes repUcating ceUs (Miller et al, 1990) , the ttansduction efficiency at various times after performing portal branch occlusion should reflect the percentage of repUcating cells at that timepoint. To test this hypothesis, BrdU was injected into selected rats 4 hr prior to injection of rettovttal vector, and a Uver biopsy was obtained from a nonoccluded lobe at the time of rettovttal vector injection. Because only repUcating cells incorporate BrdU into thett DNA, the percentage of ceUs that repUcated during this 4-hr interval could be determined by immunostaining using anti-BrdU antibodies. Figure  2A demonsttates the absence of labeled cells in a nonregenerating liver from an animal that received the sham procedure. Figure 2 , B-D, demonsttates that 33% of hepatocytes repUcated between 20 and 24 hr after performing 70% partial hepatectomy, which is consistent with previous data from other investigators (Grisham, 1962) . Figure 2 , E and F, demonsttates diat 24% of the hepatocytes repUcated between 44 and 48 hr after performing PBO.
The percentage of cells that were replicating at various times after PBO is shown in Fig. 3 . Only 0.1% of hepatocytes incorporated BrdU between 14 and 18 hr after PBO, demonsttating that hepatocyte DNA repUcation had not yet begun. For most rats, approximately 10% of hepatocytes repUcated over 4-hr intervals between 20 and 32 hr after PBO, whereas approximately 20% of hepatocytes repUcated over 4-hr intervals between 32 and 40 hr after PBO. The peak labeUng index of 28% was achieved between 40 and 44 hr after PBO. The labeUng index decUned to 23.9% and 19% at 44-48 hr and 48 to 52 hr after PBO, respectively.
Morbidity and mortality of PBO
Rats resumed normal activity and food intake witiiin 1 hr following die PBO procedure. In conttast, rats were lediargic and had piloerection for at least 2 hr after tiie 70% partial hepatectomy procedure. The overall mortality of rats tiiat received PBO/rettoviral vector injection widiout Uver biopsy in tiiis ex-tomy/rettovttal vector injection for animals that did not rece periment was 13%, as shown in Table 1 . Although tiiis was a Uver biopsy, tiie difference was not statistically significant by lower tiian the 33% mortaUty rate seen with partial hepatec-using the chi-square test. . 3 . Labeling index. BrdU incorporation was assessed as described in Fig. 2 and die labeUng index was detemiined by dividing the number of BrdU-positive nuclei by the total number of nuclei. Data shown represent the percentage of cells from an individual rat that repUcated during the labeUng period (±SEM). The timepoint shown on the graph represents the middle of the labeUng period.
Liver function tests were also evaluated to determine if PBO resulted in hepatocellular necrosis or impairment of Uver fiinction. SGPT is released from a ceU that undergoes lysis and semm levels can be used to quantitate the degree of hepatocellular damage. As shown in Fig. 4 , the SGPT was two-fold higher than the upper Umit of normal at 3 days after PBO, and was within normal Umits at 4 or 9 days after PBO. SGPT levels were normal at these timepoints after partial hepatectomy. Total bilimbin levels were normal at the same timepoints after PBO or partial hepatectomy (data not shown). We conclude that PBO does not induce significant levels of hepatocellular necrosis or compromise billimbin secretion.
DISCUSSION
The in vivo deUvery of Mo-MLV-based rettovttal vectors to the Uver has been demonsttated in mice (Lieber et al, 1995a,b) , rats (Rettuiger et al, 1994) , and dogs (Cardoso et al, 1993;  Days after Procedure I I Portal Branch Occlusion
•li Partial Hepatectomy   FIG. 4 . SGPT levels after PBO or partial hepatectomy. Sera collected from animals at 3-9 days after PBO or partial hepatectomy were analyzed for SGPT levels. The average SPOT ui Sigma-Frankel Units/ml ± SEM is reported. The 95% confidence intervals for normal rats is 0-30 U/ml. Kay et al, 1993) . Although this resuhs in stable expression of reporter genes if the appropriate promoter is chosen, its major drawback is the need to induce Uver ceU repUcation by administtation of a Uver toxin or by surgical removal of 70% of the Uver. Two approaches might be taken to eliminate this requttement: (i) alter the rettovttal vector to aUow it to ttansduce nondividing ceUs; or (u) identify less toxic methods for inducing hepatocyte repUcation. Elements of the human immunodeficiency viras (HTV) were recently utiUzed to develop a rettovttal vector that could ttansduce nondividing neuronal ceUs in vivo (Naldini et al, 1996) . It is unclear, however, if this vector will efficienfly ttansduce other cell types such as hepatocytes in vivo. In addition, HTV-based rettovttal vectors might ttansduce blood or endotheUal cells during in vivo administtation, which might increase the number of total integration events The overall mortaUty rate of 70% partial hepatectomy followed by rettovttal vector injection or 70% PBO followed by rettovttal vector injection is reported. "Historical conttols represent rats diat have received a partial hepatectomy combined witil inttaportal injection of rettovttal vector over tiie past 2 years. AU of tiiese operations were performed by die same surgeon in die same facility. The number of animals diat died over the total number of animals of tiiat group is reported, widi die percentage of rats that died in parentheses.
"For Experiment 1 A, the increased mortaUty rate may have been due to ttie addition of a Uver biopsy procedure or the relative inexperience of die surgeon witii tiie PBO procedure.
Tor Experiments IB and 2, no liver biopsy was perfonned, and die surgeon had more expenence with the PBO procedure.
in an animal, consequently increasing die risk of insertional mutagenesis. Thus, die marked selectivity of Mo-MLV-based rettovttal vectors for replicating hepatocytes in vivo is an advantage, provided diere are safe mediods for inducing hepatocyte rephcation.
Efficacy of PBO at facilitating retroviral transduction
We demonsfrate here diat PBO can faciUtate rettovttal vector ttansduction of hepatocytes in vivo. Injection of a single dose of rettovkal vector between 24 and 48 hr after PBO resulted in reporter gene expression tiiat was approximately 20-50% as high as that observed after injection of refrovttal vector at 24 hr after performing a partial hepatectomy. The lower ttansduction efficiency is probably due to the fact that die average labeUng index in hepatocytes from the nonoccluded Uver (10-28%) during all 4-hr intervals between 20 and 52 hr after PBO was lower tiian the labeling index (33%) that was observed at 20-24 hr after performing a partial hepatectomy. Our labeUng uidex results differ sUghtly from a previous stady diat demonsttated diat 18%, 7%, and 4% of rat hepatocytes incorporated tiitiated tiiymidine at 22-24,46-48, or 70-72 hr, respectively, after occlusion of portal vein branches that provided blood to 70% of the liver (Rozga et al, 1986) . These differences might be due to sUght variations in the surgical techiuque, utilization of thymidine instead of BrdU, or variations in the time and dittation of adminisfration of the nucleotides relative to PBO. Although in diis stady the semm hAAT levels diat were observed when the refrovttal vector was injected at 24 or 28 hr after PBO appear to be higher than diey should be based upon the BrdU labeUng index, the ratio of seram hAAT to tiie labeUng index was not significantly different from the ratio obtained when the refrovttal vector was injected at 36 hr after PBO. The prolonged period during which refrovttal vector fransduction could occitt after performing PBO suggests that multiple injections of rettovttal vector over the period between 24 and 48 hr should resuh in a higher overaU fransduction efficiency. In conttast, the fransduction efficiency decUnes rapidly in rats (Kolodka era/., 1993; Branchereau era/., 1994) and mice (Lieber et al., 1995a) after the peak labeling index is obtained at 24 and 48 hr, respectively, after performing partial hepatectomy. We are currently testing the hypothesis that multiple injections of refrovttal vector between 24 and 48 hr after PBO wiU result in a higher overall fransduction efficiency in rats.
Mortality and morbidity of PBO
It is important to assess the mortaUty and morbidity of any proceditte that might be used in human patients for gene therapy. In this stady, the mortality rate in rats after PBO/refroviral vector injection (13%) appeared to be lower than that of partial hepatectomy/refrovttal vector injection (33%), although an insufficient number of arumals were analyzed to achieve statistical significance. The mortaUty rate should be lower or even zero in larger animals, where PBO and refrovttal vector injection could be performed by minimally invasive techniques. PBO to >50% of the Uver has been used in humans in an attempt to freat Uver cancer, and no mortaUties have been reported (Honjo et al, 1975; Kinoshita et al, 1986; Makuuchi et al, 1991; DeBaere et al., 1993) . In humans, the portal vein can be accessed by percutaneous ttanshepatic punctitte (Burcharth, 1979) , cadieterization of die umbiUcal vein (Carbalhaes, 1959) , or ttansjugular ttanshepatic puncture (Rosch et al, 1969) . Branches of die portal vein can dien be occluded using emboUc material, as was done in 21 human patients widiout compUcations (Kinoshita et al, 1986) . Finally, die catheter could be left in die portal vein for subsequent infusion of the retrovttal vector.
Another important consideration is whedier or not the method for inducing hepatocyte replication compromises liver functions. This would be of particular importance when using gene ttierapy to tteat metaboUc disorders such as omithine ttanscarbamylase deficiency, in which a partial decUne in Uver fiinction might lead to immediate death due to worsening of the metaboUc state. In tiiis stady, the biUmbin level did not increase in any animal for up to 2 weeks after PBO. The maintenance of Uver fiinction is probably due to the fact that 30% of hepatocytes were unscathed, and presumably fiilly functional, after the PBO procedure was performed. As previously reported (Steiner and Martinez, 1961; Rozga et al, 1986) , die occluded lobes attophied to ~ 10% of thett original volume, whereas the nonoccluded lobes enlarged to approximately three times thett original size at 8 weeks after PBO (data not shown). Although Uver fiinctions appeared to be maintained in this stady, more sensitive measures of liver function wiU need to be assessed in larger animals after performing PBO to confirm its safety.
There was little evidence of hepatocellular necrosis in diis stady, because the SGPT levels were two-fold higher than the upper Umit of normal at 3 days after PBO and within normal Umits thereafter. Our results are consistent with previous stadies demonsttating that rats that underwent PBO had normal semm glutamic-oxaloacetic ttansaminase (SGOT) levels at 24 hr or later after Ugation, although there was a 90-fold elevation in SGOT at 12 hr (Ozawa et al, 1973) . Rabbits and humans had a 15-fold (Ozawa et al, 1973) and 6-to 10-fold (Ozawa et al, 1973; Makuuchi et al, 1991 ) elevation in SGOT levels over baseUne values, respectively, during the fttst week after occlusion of portal vein branches, and levels feU to baseUne within days. Four dogs had no elevation of Uver enzymes after occlusion of the portal vein branches that served the left lobe, although one dog had a two-fold elevation in SPGT (Yamakado et al, 1995) . The siuprisingly low amount of hepatocellular necrosis is consistent with the fact that the major mechanism of cell death after PBO is apoptosis, although some investigators have observed centrilobular necrosis (Kerr, 1971; Rozga et al, 1986; Ikeda et al, 1995) .
The maintenance of Uver-specific functions and the paucity of hepatoceUular damage observed after PBO is a potential advantage of this method over the utiUzation of hepatotoxins for inducing hepatocyte repUcation. When wild-type urokinase plasminogen activator (uPA) was expressed from an adenovttal vector in the Uvers of mice, the SGPT was >600 U/ml for at least 6 consecutive days, and >30% ofthe hepatocytes repUcated per day for at least 9 consecutive days. Administtation of an adenovttal vector that encoded a modified uPA gene whose protein product accumulated inttacellularly resulted in elevation of the SGPT to >2(K) U/ml for 3 consecutive days, and repUcation of >30% of the hepatocytes per day for at least 9 consecutive days (Lieber et al, 1995b) . The results of other Uver fimction tests and mortaUty rates were not reported tti eidier stady. Thus, although adnunistration of a uPA-expressing adenovttal vector was as efficient as partial hepatectomy at faciUtatuig rettovttal vector fransduction, its toxicity might resuU in deatii due to Uver insufficiency in some patients. Admmisttation of Uver toxins might be acceptable for use in humans if one could identify a dose that faciUtates rettovttal vector ttansduction without causing death due to Uver ttisufficiency in any animals. Even if this resulted in a relatively low ttansduction efficiency for each cycle, it might be possible to repeat die procedure to achieve a higher overaU ttansduction efficiency.
Implications for gene therapy
Rettovttal vectors show considerable promise for use in gene therapy because they integrate into the chromosome, resulting in stable expression of a gene if the appropriate promoter is used.
It is unclear what approach should be used to achieve rettovttal vector ttansduction of hepatocytes in vivo. Although an HTV-based rettovttal vector was recently reported to ttansduce nondividing neuronal cells in vivo (Naldini et al, 1996) , it has not yet been reported to fransduce hepatocytes in vivo, and its promiscuity might present a problem after injection of the vector into the portal vein. A major advantage of deUvering Mo-MLV-based refrovttal vectors to animals with regenerating livers is its abiUty to fransduce hepatocytes selectively. Several methods have been used to induce hepatocyte repUcation in animals to faciUtate refrovttal vector fransduction. Although 70% partial hepatectomy has been the most commonly used method, this is a major operation in humans and would probably have a operative risk approaching 5% (M.W.F., personal communication). Adminisfration of a Uver toxin such as carbon tefrachloride (Kaleko et al, 1991) or an adenovttal vector that encodes uPA (Lieber et al, 1995a,b ) is effective at faciUtating rettovttal vector ttansduction, but might result in death due to Uver insufficiency in some patients. The PBO procedure described here has several advantages. Fttst, PBO induces programmed cell death and compensatory repUcation for a Umited period of time. Second, PBO is easily conttolled and leaves 30% of the hepatocytes unscathed. Thttd, PBO does not requtte a surgical procedure in humans. The risks of PBO include the possibiUty of portal vein thrombosis or of ttansient Uver insufficiency. Future experiments in which different approaches are dttectiy compared for efficacy and morbidity will need to be performed to determine which, if any, will be acceptable for use in humans for the purpose of gene therapy.
